http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003129631-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2002-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d243eac7b8897ea488195a808981b1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cef08c12c536e1c84338140560222ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfab25ad73a77ed335fc462cd3262b53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b053fd88c73a3c397c2e069a41b732b0 |
| publicationDate | 2003-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003129631-A1 |
| titleOfInvention | Gene family with transformation modulating activity |
| abstract | pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade ≧5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation. In contrast, cancer-associated pp32 variants augment, rather than inhibit, transformation. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6930175-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9724430-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006057616-A1 |
| priorityDate | 1997-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 582.